Editorial Open Access

CURRENT SCENARIO OF THERAPEUTICS FOR EBOLA VIRUS DISEASE

ML Arvinda Swamy1, Madhavan P.N. Nair1 and Shailendra K. Saxena1
  • 1 Florida International University, United States

Abstract

Currently various countries in Africa, including Liberia, Sierra Leone, Guinea, Nigeria, are facing disaster due to Ebola Virus Disease (EVD), which is primarily caused by Ebola virus. 2014 outbreak of Ebola associated viral haemorrhagic fever has 55-60% fatality rate. The incubation period of Ebola is below 21 days; once the appearance of symptoms starts the person will be infective. As there is no specific vaccine, antiviral or drugs for treating Ebola resulting in large number of deaths. Most of the recent outbreaks occurred in remote areas of West Africa. Poverty, lack of awareness, access to health centres, human habitats taking its toll in spreading the disease in large scale. Few nucleotide analogues, protease inhibitors, receptor binding, monoclonal antibodies and anticoagulant therapies are exhibiting promising role in inhibiting the Ebola virus in various (in vitro and in vivo) models.

American Journal of Infectious Diseases
Volume 10 No. 3, 2014, 100-104

DOI: https://doi.org/10.3844/ajidsp.2014.100.104

Submitted On: 1 September 2014 Published On: 3 September 2014

How to Cite: Swamy, M. A., Nair, M. P. & Saxena, S. K. (2014). CURRENT SCENARIO OF THERAPEUTICS FOR EBOLA VIRUS DISEASE. American Journal of Infectious Diseases, 10(3), 100-104. https://doi.org/10.3844/ajidsp.2014.100.104

  • 4,296 Views
  • 3,071 Downloads
  • 1 Citations

Download

Keywords

  • Ebola
  • Ebola Virus Disease
  • EVD
  • Filovirus
  • Therapeutics
  • EHF
  • Viral Haemorrhagic Fever1